We are a partner of choice for academic and industrial research collaboration around the world – bringing in complementary perspectives, diverse areas of expertise, emerging technologies and disruptive concepts. Partnerships extend our ability to serve the needs of healthcare professionals and patients, helping to advance global health.
We are a global pioneer and leader in medical aesthetics. Our portfolio has a strong medical and scientific basis and is present in approximately 90 countries. We support innovation that improves and develops medical solutions and services in the minimally invasive aesthetics field, from early research to commercially available solutions and products.
Our flagship brand Cetaphil® is a leader in consumer skincare and has a global footprint. With innovation at the heart of our growth models, we are dedicated to answering the multiple skin care needs of sensitive skin and acne sufferers. We seek partnership opportunities at various stages of development relevant to consumers and endorsed by healthcare professionals.
We look for innovative compounds that can be developed and commercialized as products to provide breakthrough therapies for dermatological conditions and unmet needs. Our scope of interest includes small and large molecules, with a focus on systemic orals and biologics, though we consider all routes of administration.
Our priority disease targets include immune-mediated inflammatory skin diseases, particularly atopic dermatitis and psoriasis, as well as other skin diseases, such as non-melanoma skin cancers and rare dermatological diseases.
We have the capabilities to onboard a partnered compound or product at any stage and are open to pre-clinical, clinical or commercial-stage assets.
If you are interested in partnering with Galderma, please contact our Business Development Department by email via the contact form.